MedTrace Logo

Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD

NCT05530096 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2025-04-03

No results posted yet for this study

Summary

The purpose :

Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.

Conditions

Interventions

DIAGNOSTIC_TEST

Standard of care

Participants will not receive any intervention in this study. Participants will receive standard of care therapy

Sponsors & Collaborators

  • Sir Mortimer B. Davis - Jewish General Hospital

    lead OTHER

Principal Investigators

  • Rayan Kaedbey · Sir Mortimer B. Davis - Jewish General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2027-09-30
Completion
2028-09-30
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05530096 on ClinicalTrials.gov